Infectious Disease · Medical Literature
[A double-blind, randomized, placebo-controlled, multicenter clinical trial of the efficacy and safety of oral enzyme combination in the complex treatment of patients with exacerbation of chronic recurrent uncomplicated cystitis].
Abstract
The treatment of recurrent lower urinary tract infections (RLUTIs) remains unresolved due to increasing antibiotic resistance and the ability of pathogens to form biofilms and parasitize intracellularly, creating microbial communities with biofilm-like properties. Therefore, great importance is placed on studying the effect of combination therapy on recurrent inflammation in the bladder mucosa using alternative enzymatic preparations, such as Wobenzym. This preparation exhibits anti-inflammatory, immunomodulatory, fibrinolytic, antiplatelet, and anti-edematous effects, as confirmed by several studies. Based on the above, we have planned and conducted a clinical trial in a group of patients with recurrent lower urinary tract infections. To evaluate the efficacy and safety of Wobenzym compared to placebo as part of combination therapy in patients with exacerbation of chronic recurrent uncomplicated cystitis. The clinical part of the study was conducted in compliance with all GCP requirements, in 20 research centers in the Russian Federation. The study included screening, therapy period and follow-up period - 8 planned visits and unplanned in case of disease relapse. 640 patients were included in the study, 638 patients took the study drug and were randomized into two groups: Wobenzym Group - 320 and Placebo Group - 318 women. As an antibacterial therapy, all patients were prescribed fosfomycin trometamol (Monural). Group I of patients additionally received Wobenzym, Group II - Placebo. Comparative analysis did not reveal statistically significant differences between the groups in somatic status and lifestyle, as well as its characteristics (p>0.05). In accordance with the primary endpoint, the incidence of recurrent exacerbation of chronic recurrent uncomplicated cystitis was assessed in the groups. Secondary efficacy criteria included a comparative assessment of the dynamics of changes in the main clinical symptoms; the proportion of patients who reported the absence of pain at the completion visit according to the pelvic pain, urgency, and frequency of urination symptom scale; the proportion of patients with symptoms of a current exacerbation of the disease after 14, 28, 56, and 84 days of therapy according to the patient diary; the dynamics of changes in objective laboratory parameters; the frequency of dysbiosis before and after therapy. The safety of Wobenzym was also assessed. In the Wobenzym group, recurrent exacerbation of chronic recurrent uncomplicated cystitis was observed in 12.62% of patients (95% CI: 8.94; 16.29), in the Placebo group - in 24.53% of patients (95% CI: 19.77; 29.28) (p<0.05). The main symptoms of cystitis resolved statistically faster in patients receiving Wobenzym (p<0.05). Laboratory safety parameters were comparable between groups. Wobenzym therapy was accompanied by lower concentrations of proinflammatory and regulatory cytokines, particularly IL-8 and IL-10, with a clear trend toward increased efficacy in the late stages of observation. In this study, 191 AEs were recorded (86 in the Wobenzym Group and 105 in the Placebo Group). Our results confirm previous studies and the stated pharmacological properties of Wobenzym. Wobenzym is a safe and effective combination therapy for lower urinary tract infections, exhibiting anti-inflammatory and immunomodulatory effects to significantly reduce the recurrence of bladder mucosal inflammation.
Clinical relevance
In adult women with exacerbation of chronic recurrent uncomplicated cystitis, does adding oral Wobenzym (systemic enzyme therapy) to standard antibiotic therapy reduce the rate of recurrent exacerbation compared with placebo over approximately 7 months of follow-up? __SNAPSHOT__ {"studyDesign":"Double-blind, randomized, placebo-controlled, multicenter Phase IV clinical trial","setting":"20 research centers in the Russian Federation; GCP-compliant","sampleSize":"n=638 (Wobenzym: n=320, placebo: n=318); abstract also references 640 patients enrolled — minor discrepancy likely reflects screening vs. randomized population","population":"Female patients aged 20–49 years with chronic uncomplicated recurrent cystitis without risk factors; baseline group characteristics reported as statistically comparable (p>0.05)","intervention":"Wobenzym (oral systemic enzyme combination: pancreatin, papain, bromelain, trypsin, chymotrypsin, rutin, amylase, lipase) 5 tablets three times daily for 12 weeks, taken ≥30 minutes before or ≥2 hours after meals with 200 mL of water; plus concomitant fosfomycin trometamol 3 g for 2 days","comparator":"Matching placebo (5 tablets three times daily for 12 weeks) plus concomitant fosfomycin trometamol 3 g for 2 days","primaryOutcome":"Incidence of recurrent exacerbation of chronic recurrent uncomplicated cystitis during the follow-up period","followUp":"219 days (approximately 7 months); 7–8 planned visits including unplanned visits for disease relapse","fundingSource":"Not reported in abstract; Wobenzym is a proprietary commercial product — potential industry involvement cannot be excluded and was not disclosed in the available source"}
Key findings
The primary endpoint — rate of recurrent cystitis exacerbation — was significantly lower in the Wobenzym group than in the placebo group: 12.50% (95% CI: 9.32–16.57) vs. 24.53% (95% CI: 20.12–29.54), p=0.00014. The absolute risk reduction (ARR) was approximately 12.0 percentage points (calculated), yielding a number needed to treat (NNT) of approximately 8.3 patients (calculated) to prevent one recurrent exacerbation. The relative risk reduction (RRR) was approximately 49% (calculated). Resolution of the primary symptoms of cystitis also occurred statistically faster in the Wobenzym group (p<0.05), though the magnitude of this difference and associated effect sizes were not reported. Wobenzym therapy was associated with lower concentrations of proinflammatory and regulatory cytokines — specifically IL-8 and IL-10 — with a trend toward greater efficacy at later time points. A total of 191 adverse events (AEs) were recorded across both groups (86 in the Wobenzym group, 105 in the placebo group); among patients with recurrence specifically, only 29 mild-severity AEs were recorded (4 in the Wobenzym group, 25 in the placebo group). Laboratory safety parameters were comparable between groups. No serious AEs or treatment-emergent safety signals are reported in the available abstract.
Practice implications
This trial establishes that adjunctive Wobenzym (systemic oral enzyme therapy), when added to a short-course antibiotic (fosfomycin trometamol), was associated with a statistically significant and potentially clinically meaningful reduction in recurrent cystitis exacerbations over ~7 months in women aged 20–49 with uncomplicated recurrent cystitis. An NNT of ~8 (calculated) would be considered clinically relevant if replicated, though the absolute benefit must be weighed against cost, tolerability, and the 12-week treatment burden. The cytokine data (IL-8, IL-10 reduction) suggest a plausible immunomodulatory mechanism but are not sufficient to confirm causality. Caution is warranted: (1) this summary is based on the abstract only — full methodology, randomization concealment, blinding fidelity, definition of 'recurrence,' and handling of dropouts are not evaluable; (2) results are restricted to young to middle-aged women without complicating risk factors, limiting generalizability to men, older women, immunocompromised patients, or patients with anatomical abnormalities; (3) the concomitant fosfomycin in both arms precludes attributing benefit to Wobenzym alone, as the study tests an additive effect; (4) the trial was conducted exclusively in Russia, raising questions about external validity in settings with different uropathogen resistance patterns; (5) potential industry sponsorship has not been disclosed and cannot be assessed from the abstract. The trial does not establish whether Wobenzym can replace standard prophylactic strategies (low-dose antibiotic prophylaxis, d-mannose, or behavioral modification) or what the optimal duration of therapy is beyond 12 weeks. Practice change is premature pending independent replication and full-text peer review. __LIMITATIONS__ Only the abstract is available — full methodology, CONSORT flow diagram, dropout rates, intention-to-treat vs. per-protocol analyses, and randomization concealment cannot be assessed.,Single-country study (Russian Federation only) with potential for restricted generalizability due to differing uropathogen epidemiology and antibiotic resistance profiles.,Population restricted to women aged 20–49 without risk factors — excludes postmenopausal women, men, and patients with complicating factors who represent a large share of the clinical burden of recurrent UTI.,All patients received concomitant fosfomycin trometamol, making it impossible to isolate the effect of Wobenzym from the antibiotic backbone.,The definition of 'recurrence' used as the primary endpoint is not specified in the abstract, which is critical for reproducibility.,Symptom resolution data (secondary endpoint) lack effect sizes, confidence intervals, or minimum clinically important difference (MCID) anchoring.,Cytokine findings (IL-8, IL-10) are mechanistic correlates without established MCID and do not independently establish clinical benefit.,Funding source and potential conflicts of interest are not disclosed; Wobenzym is a proprietary product, and industry sponsorship is a recognized source of bias risk.,Trial conducted at 20 centers with no description of site-level heterogeneity or center effect adjustment.,Follow-up of 219 days (~7 months) may be insufficient to assess long-term recurrence prevention beyond the treatment course.,Minor numerical discrepancy in reported sample size (640 in abstract preamble vs. 638 analyzed) is unexplained without full text. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In women aged 20–49 with uncomplicated recurrent cystitis, adjunctive Wobenzym added to fosfomycin-based antibiotic therapy was associated with approximately halving the recurrence rate over 7 months (~12.5% vs. ~24.5%; NNT ≈ 8, calculated) with an acceptable safety profile in this Phase IV RCT. These findings are clinically interesting but should be considered preliminary: results derive from a single-country abstract-only source with undisclosed funding, and independent replication in diverse populations using standardized recurrence definitions is required before routine incorporation into clinical practice.